National Heart and Lung Institute (F.M., U.T., R.J.B., W.M., A.W., N.W., R.G., E.M., T.J.W.D., L.E.F., M.A., P.I.T., E.E., A.J.B., A.M.R., P.J.R.B., S.K.P., S.A.C., J.S.W.), Imperial College London, United Kingdom.
Cardiovascular Research Centre, Royal Brompton and Harefield National Health Service Foundation Trust, London, United Kingdom (F.M., U.T., R.J.B., W.M., A.W., N.W., R.G., E.M., L.E.F., M.A., P.I.T., E.E., A.J.B., A.A.P., A.M.R., P.J.R.B., S.K.P., S.A.C., J.S.W.).
Circulation. 2020 Feb 4;141(5):387-398. doi: 10.1161/CIRCULATIONAHA.119.037661. Epub 2020 Jan 27.
Dilated cardiomyopathy (DCM) is genetically heterogeneous, with >100 purported disease genes tested in clinical laboratories. However, many genes were originally identified based on candidate-gene studies that did not adequately account for background population variation. Here we define the frequency of rare variation in 2538 patients with DCM across protein-coding regions of 56 commonly tested genes and compare this to both 912 confirmed healthy controls and a reference population of 60 706 individuals to identify clinically interpretable genes robustly associated with dominant monogenic DCM.
We used the TruSight Cardio sequencing panel to evaluate the burden of rare variants in 56 putative DCM genes in 1040 patients with DCM and 912 healthy volunteers processed with identical sequencing and bioinformatics pipelines. We further aggregated data from 1498 patients with DCM sequenced in diagnostic laboratories and the Exome Aggregation Consortium database for replication and meta-analysis.
Truncating variants in and were associated with DCM in all comparisons. Variants in , and were significantly enriched in specific patient subsets, with the last 2 genes potentially contributing primarily to early-onset forms of DCM. Overall, rare variants in these 12 genes potentially explained 17% of cases in the outpatient clinic cohort representing a broad range of adult patients with DCM and 26% of cases in the diagnostic referral cohort enriched in familial and early-onset DCM. Although the absence of a significant excess in other genes cannot preclude a limited role in disease, such genes have limited diagnostic value because novel variants will be uninterpretable and their diagnostic yield is minimal.
In the largest sequenced DCM cohort yet described, we observe robust disease association with 12 genes, highlighting their importance in DCM and translating into high interpretability in diagnostic testing. The other genes analyzed here will need to be rigorously evaluated in ongoing curation efforts to determine their validity as Mendelian DCM genes but have limited value in diagnostic testing in DCM at present. This data will contribute to community gene curation efforts and will reduce erroneous and inconclusive findings in diagnostic testing.
扩张型心肌病(DCM)具有遗传异质性,在临床实验室中已经测试了超过 100 种所谓的疾病基因。然而,许多基因最初是根据候选基因研究确定的,这些研究没有充分考虑背景人群的变异。在这里,我们在 56 个常检测基因的蛋白质编码区域中,定义了 2538 名 DCM 患者的罕见变异频率,并将其与 912 名确诊的健康对照者和 60706 名个体的参考人群进行比较,以确定与显性单基因 DCM 具有稳健关联的可临床解释的基因。
我们使用 TruSight Cardio 测序面板评估了 1040 名 DCM 患者和 912 名健康志愿者中 56 个潜在 DCM 基因的罕见变异负担,这些患者和志愿者使用相同的测序和生物信息学管道进行处理。我们进一步汇总了在诊断实验室和外显子组聚合联盟数据库中测序的 1498 名 DCM 患者的数据,用于复制和荟萃分析。
截断变异在 和 中与 DCM 在所有比较中均相关。在特定的患者亚组中, 、 和 中的变异明显富集,后 2 个基因可能主要导致早发性 DCM。总体而言,这些 12 个基因中的罕见变异可能解释了门诊队列中 17%的病例,该队列代表了广泛的成年 DCM 患者,在家族性和早发性 DCM 富集的诊断转诊队列中,解释了 26%的病例。尽管其他基因没有明显的多余,但不能排除它们在疾病中的有限作用,因为新的变异将无法解释,其诊断效果也最小。
在迄今为止描述的最大规模的测序 DCM 队列中,我们观察到与 12 个基因的稳健疾病关联,这突出了它们在 DCM 中的重要性,并转化为诊断测试中的高可解释性。在这里分析的其他基因需要在正在进行的基因整理工作中进行严格评估,以确定它们作为孟德尔 DCM 基因的有效性,但目前在 DCM 的诊断测试中价值有限。这些数据将有助于社区基因整理工作,并减少诊断测试中的错误和不确定结果。